$15.61
0.64% yesterday
Nasdaq, Sep 03, 10:00 pm CET
ISIN
US05463X1063
Symbol
AXGN

AxoGen, Inc. Stock price

$15.61
+3.06 24.38% 1M
-3.68 19.08% 6M
-0.87 5.28% YTD
+2.46 18.71% 1Y
+6.44 70.23% 3Y
+3.86 32.85% 5Y
+10.96 235.70% 10Y
+14.71 1,633.67% 20Y
Nasdaq, Closing price Wed, Sep 03 2025
-0.10 0.64%

Key metrics

Basic
Market capitalization
$718.3m
Enterprise Value
$736.3m
Net debt
$18.1m
Cash
$29.9m
Shares outstanding
45.8m
Valuation (TTM | estimate)
P/E
negative | 60.0
P/S
3.5 | 3.2
EV/Sales
3.6 | 3.3
EV/FCF
212.2
P/B
6.4
Financial Health
Equity Ratio
51.0%
Return on Equity
-9.6%
ROCE
1.0%
ROIC
-
Debt/Equity
0.4
Financials (TTM | estimate)
Revenue
$203.3m | $224.2m
EBITDA
$9.3m | $25.0m
EBIT
$1.7m | $3.9m
Net Income
$-4.7m | $11.9m
Free Cash Flow
$3.5m
Growth (TTM | estimate)
Revenue
17.2% | 19.7%
EBITDA
271.7% | 450.2%
EBIT
114.0% | 219.2%
Net Income
71.8% | 219.5%
Free Cash Flow
123.2%
Margin (TTM | estimate)
Gross
74.3%
EBITDA
4.6% | 11.2%
EBIT
0.8%
Net
-2.3% | 5.3%
Free Cash Flow
1.7%
More
EPS
$-0.1
FCF per Share
$0.1
Short interest
6.8%
Employees
452
Rev per Employee
$410.0k
Show more

Is AxoGen, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

AxoGen, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

14 Analysts have issued a AxoGen, Inc. forecast:

13x Buy
93%
1x Hold
7%

Analyst Opinions

14 Analysts have issued a AxoGen, Inc. forecast:

Buy
93%
Hold
7%

Financial data from AxoGen, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
203 203
17% 17%
100%
- Direct Costs 52 52
31% 31%
26%
151 151
13% 13%
74%
- Selling and Administrative Expenses 123 123
4% 4%
60%
- Research and Development Expense 27 27
6% 6%
13%
9.29 9.29
272% 272%
5%
- Depreciation and Amortization 7.58 7.58
11% 11%
4%
EBIT (Operating Income) EBIT 1.71 1.71
114% 114%
1%
Net Profit -4.66 -4.66
72% 72%
-2%

In millions USD.

Don't miss a Thing! We will send you all news about AxoGen, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AxoGen, Inc. Stock News

Neutral
Investors Business Daily
10 days ago
Shares of Axogen plunged Monday after the FDA delayed the expected approval date for the company's nerve graft product.
Neutral
GlobeNewsWire
10 days ago
ALACHUA, Fla. and TAMPA, Fla.
Neutral
Seeking Alpha
23 days ago
Axogen is compounding business capital at increasing returns which was reflected in Q2 earnings. The stock remains in a down-trend with investors compressing multiples paid on capital invested into the business. The range of potential outcomes remains broad which coincides with historical trends seen in market for this name.
More AxoGen, Inc. News

Company Profile

AxoGen, Inc. engages in the development and market of surgical solutions for peripheral nerves. It also provides products and education to improve surgical treatment algorithms for peripheral nerve damage or discontinuity. Its products include avance nerve graft, axoguard nerve connector, axoguard nerve protector, avive soft tissue membrane, acroval neurosensory and motor testing system, and axotouch two-point discriminator. The company was founded in 1977 and is headquartered in Alachua, FL.

Head office United States
CEO Michael Dale
Employees 452
Founded 1977
Website www.axogeninc.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today